Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Chongqing Claruvis Pharmaceutical Co. Ltd. has 2 pending office actions in Chemistry & Materials. The matters are assigned to 2 distinct examiners and 2 distinct art units, showing that the pending work spans separate examination contexts.
CARREON, ADRIAN JOHN is the busiest examiner, with 1 pending matter. The examiner handles one part of the reported activity. Counsel should coordinate the chemical prosecution positions while adapting each response to its assigned examiner and art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CARREON, ADRIAN JOHN | 1 | 80.0% | +33.3% |
| EIX, EMILY FAY | 1 | 45.7% | +76.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547971 | CELL LYSIS BUFFER SEPARATION APPARATUS FOR PREPARING POLYPEPTIDE, AND SYSTEM AND APPLICATION THEREOF | CARREON, ADRIAN JOHN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547979 | MODIFIED NEUROTOXIN SINGLE-CHAIN POLYPEPTIDE AND USE THEREOF | EIX, EMILY FAY | 22d |
| 18547971 | CELL LYSIS BUFFER SEPARATION APPARATUS FOR PREPARING POLYPEPTIDE, AND SYSTEM AND APPLICATION THEREOF | CARREON, ADRIAN JOHN | — |
| Art Unit | Apps |
|---|---|
| 1799 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547971 | CELL LYSIS BUFFER SEPARATION APPARATUS FOR PREPARING POLYPEPTIDE, AND SYSTEM AND APPLICATION THEREOF | CARREON, ADRIAN JOHN | 1799 | §103§112 | Final Rejection | — | Pending | Aug 25, 2023 |
| 18547979 | MODIFIED NEUROTOXIN SINGLE-CHAIN POLYPEPTIDE AND USE THEREOF | EIX, EMILY FAY | 1653 | §103Other | Final Rejection | 22d | Pending | Aug 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChongqing Claruvis Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Adrian John Carreon has the most, with 1 of Chongqing Claruvis Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
